Nucleic acid respiratory syncytial virus vaccines
AssigneeConnaught Laboratories Limited
InventorsXiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
Life of this patent
Estimating the term…
Abstract
Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
Claims16
A method of immunizing a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises administering to said host an effective amount of a plasmid vector comprising a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV F protein or fragment thereof in said host, and a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence and comprising a pair of splice sites to prevent aberrant mRNA splicing and to increase expression of said RSV F protein or fragment thereof in vivo from said vector in said host.
A method of using a gene encoding an RSV F protein or a RSV F protein fragment which generates antibodies that specifically react with RSV F protein to produce an immune response in a host, which comprises:
- isolating said gene;
- operatively linking said gene to a nucleotide sequence comprising a pair of splice sites to prevent aberrant mRNA splicing and to increase expression of said RSV F protein or fragment thereof in said host;
- operatively linking said gene to at least one promoter sequence to produce a plasmid vector wherein said nucleotide sequence is located between said promoter sequence and said gene, said promoter sequence directing expression of said RSV F protein or fragment thereof when said vector is introduced into a host to produce an immune response to said RSV F protein;
- and
- introducing said vector into the host.
A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:
- isolating a first nucleotide sequence encoding an RSV F protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein;
- operatively linking said first nucleotide sequence to at least one promoter sequence to produce a plasmid vector, the promoter sequence directing expression of said RSV F protein or fragment thereof when introduced into a host to produce an immune response to said RSV F protein;
- operatively linking said first nucleotide sequence to a second nucleotide sequence between said first nucleotide sequence and said promoter sequence in said vector, said second nucleotide sequence comprising a pair of splice sites to prevent aberrant mRNA splicing and to increase expression of said RSV F protein or fragment thereof in vivo from the vector in the host, and
- formulating said vector as a vaccine for in vivo administration.
Dependencies are inferred from the claim text.